In a strategic move to cement its leadership in the booming cardiometabolic therapeutics market, Danish pharmaceutical titan Novo Nordisk has…
Read More
Boehringer Ingelheim Eyes MASH as the Next Front for Survodutide, a GLP-1/Glucagon Receptor Dual Agonist
For decades, fatty liver disease, specifically metabolic dysfunction-associated steatotic liver disease (MASLD), and its more severe inflammatory form, metabolic dysfunction-associated…
Read More
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist
For decades, metabolic dysfunction-associated steatohepatitis (MASH), a more serious inflammatory form of fatty liver disease, remained a largely overlooked condition,…
Read More
Boehringer Ingelheim Eyes MASH as the Next Front for Survodutide, a GLP-1/Glucagon Receptor Dual Agonist
For decades, fatty liver disease, specifically its more severe inflammatory manifestation known as metabolic dysfunction-associated steatohepatitis (MASH), remained a significant…
Read More
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist
For decades, fatty liver disease, and its more severe inflammatory progression known as metabolic dysfunction-associated steatohepatitis (MASH), remained largely overlooked…
Read More
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist
Neeraja Balachander, who oversees Boehringer Ingelheim’s extensive cardio-renal-metabolic portfolio, articulated the company’s ambitious vision. “We have a program in MASH,…
Read More
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist.
For decades, metabolic dysfunction-associated steatohepatitis (MASH), the more severe inflammatory form of fatty liver disease, was a silent epidemic, often…
Read More
Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Eli Lilly’s Triple Agonist Achieves 16.8% Weight Loss in Phase 3 Trial
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Novo Nordisk’s triple agonist UBT251 delivered up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, has announced promising results from a Phase 2 trial of…
Read More
